Funded Biotechnology Startups in Zürich
Among the 17 biotechnology companies listed with Zürich addresses, funding activity spans September 2021 through July 2025.
Among the 17 biotechnology companies listed with Zürich addresses, funding activity spans September 2021 through July 2025. The largest disclosed rounds are Araris Biotech's $24M Series A (October 2022), BC Platforms' $20M Series Unknown (November 2022), and Molecular Partners' $20M Series Unknown (October 2024). Hemotune raised $16M in March 2024 and Microcaps closed a $10M Series A in June 2024.
Four deals appear in 2025: Sequana Medical ($1M Series Unknown, July), SEITO Biologics ($3M Seed, June), Arktis Radiation Detectors (undisclosed, April), and CellX Biosolutions ($2M Pre-Seed, February). The stage mix is wide — from Pre-Seed through post-IPO equity, including a $120K grant to MetrioPharm in October 2022. Six of the 17 rounds carry a "Series Unknown" label, the most common designation in the dataset.
Most recent rounds
17 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Zürich biotech companies?
The top three by disclosed amount are Araris Biotech at $24M Series A (October 2022), BC Platforms at $20M Series Unknown (November 2022), and Molecular Partners at $20M Series Unknown (October 2024). Hemotune ($16M, March 2024) and Microcaps ($10M Series A, June 2024) follow.
Which companies closed rounds in 2025?
Four companies show 2025 activity: CellX Biosolutions ($2M Pre-Seed, February), Arktis Radiation Detectors (undisclosed, April), SEITO Biologics ($3M Seed, June), and Sequana Medical ($1M Series Unknown, July).
How are funding stages distributed across the 17 listed companies?
Six rounds carry a "Series Unknown" label — the most common designation — followed by four Seed rounds and three Series A rounds. The remainder include one Pre-Seed (CellX Biosolutions), one grant (MetrioPharm, $120K), one post-IPO equity event (Xlife Sciences AG, $5M), and one round with no stage recorded (Hemotune, $16M).
Are there any non-dilutive or non-venture funding events in this dataset?
MetrioPharm received a $120K grant in October 2022. Xlife Sciences AG's $5M post-IPO equity round from January 2022 is also structurally distinct from standard venture rounds.
What date range do these 17 Zürich biotech companies cover?
The oldest listed round is IDUN Technologies' $2M Seed from September 2021; the most recent is Sequana Medical's $1M Series Unknown from July 2025, giving the dataset a span of roughly four years.
How do Seed-stage deal sizes compare to Series A rounds in this data?
The four Seed rounds range from $2M (IDUN Technologies, Oncobit) to $5M (Invasight), with SEITO Biologics at $3M. The three Series A rounds are Araris Biotech at $24M, Microcaps at $10M, and TOLREMO therapeutics at $4M — a wider spread reflecting differing company maturities at that stage.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.